Overexpression and overactivation of Akt in thyroid carcinoma

Cancer Research

Volumn 61, Issue 16, 2001, Pages 6105-6111

  Ringel, Matthew D ^a   Hayre, Nicole ^a   Saito, Jun ^b   Saunier, Bertrand ^b   Schuppert, Frank ^c   Burch, Henry ^d   Bernet, Victor ^d   Burman, Kenneth D ^a   Kohn, Leonard D ^b   Saji, Motoyasu ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b OHIO UNIVERSITY   (United States)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CANCER GROWTH; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; INSULIN; ISOENZYMES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID NEOPLASMS; THYROTROPIN; TUMOR CELLS, CULTURED;

EID: 0035881322     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer
2. Prospective multicenter study of thyrois carcinoma treatment: Initial analysis of staging and outcome
3. RET proto-oncogene in the development of human cancer
4. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas
5. The ret/PTC1 rearrangement is a common feature of Chernobyl-associated papillary thyroid carcinomas from Belarus
6. Involvement of RET oncogene in human tumours: Specificity of RET activation to thyroid tumours
7. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas tacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes
8. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas
9. Fibroblast growth factors 1 and 2 and fibroblast growth factor receptor 1 are elevated in thyroid hyperplasia
10. Functional insulin receptors are overexpressed in thyroid tumors: Is this an early event in thyroid tumorigenesis?
11. Expression of insulin-like growth factor receptors in primary human thyroid neoplasms
12. Increased activity of insulin-like growth factor-binding protein in human thyroid papillary cancer tissue
13. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis
14. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas
15. Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene
16. Ras signaling through P13K confers hormone-independent proliferation that is compatible with differentiation
17. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): Evidence for a divergence of the ERKs and JNKs pathways induced by Ret
18. PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS
19. Phosphatidylinositol-3-OH kinase as a direct target of Ras
20. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway
21. Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor
22. Signal transduction pathways activated by RET oncoproteins in PC12 pheochromocytoma cells
23. Somatic deletions and mutations in the Cowden disease gene. PTEN, in sporadic thyroid tumors
24. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
25. Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity
26. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis
27. New insights into tumor suppression; PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
28. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3.4.5.-trisphosphate and Akt/protein kinase B signaling pathway
29. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies
30. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN
31. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
32. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
33. Somatic mutations of the PTEN/MMAC1 tumor suppressor gene in sporadic follicular thyroid tumors
34. Insulin and TSH promote growth in size of PC C13 rat thyroid cells, possibly via a pathway different from DNA synthesis: Comparison with FRTL-5 cells
35. Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects
36. ReGulation of thyroid cell cycle progression and growth by insulin/IGF-1 via phosphotidylinositol 3 (OH)-kinase dependent AKT-mediated signaling
37. AKT2 a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas
38. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3
39. Identification of a human Akt3 (protein kinase B γ) which contains the regulatory serine phosphorylation site
40. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma
41. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
42. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA
43. Transforming activity and mitosis-related expression of the AKT2 oncogene: Evidence suggesting a link between cell cycle regulation and oncogenesis
44. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas
45. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines
46. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
47. Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1)
48. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas
49. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast
50. Germline mutations in PTEN are present in Bannayan-Zonana syndrome
51. Allelotype of human thyroid tumors: Loss of chromosome 11q13 sequences in follicular neoplasms
52. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival
53. Mitogenic stimulation of normal and oncogene-transformed human thyroid epithelial cells by hepatocyte growth factor
54. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells
55. AKT2, a member of the protein kinase B family, is activated by growth factors v-Ha-ras and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells
56. Multiple hamartoma syndrome (Cowden's disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma)
57. Oncoproteins and tumor progression in papillary thyroid carcinoma: Presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival
58. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer
59. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer